The 2023 ESC guidelines for the management of cardiomyopathies: the 10 commandments

Juan Pablo Kaski,Elena Arbelo

DOI: https://doi.org/10.1093/eurheartj/ehad858

IF: 39.3

2024-01-31

European Heart Journal

Abstract:The 2023 European Society of Cardiology Guidelines for the Management of Cardiomyopathies 1 represent the first international clinical practice guideline covering the full range of cardiomyopathies throughout the life course. As this is a new guideline (except for hypertrophic cardiomyopathy, for which a focused update has been provided), most of the 158 recommendations are new. Choosing the 10 most important aspects is therefore no easy task! Here, however, are 10 key themes explored in this new guideline.

cardiac & cardiovascular systems

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a comprehensive international clinical practice guideline covering the management of various cardiomyopathies throughout the life cycle. Specifically, the "Guidelines for the Management of Cardiomyopathies" released by the European Society of Cardiology (ESC) in 2023 aims to:

1. **Patient Pathway**: Emphasize the possibility of considering cardiomyopathy in common clinical manifestations (such as heart failure, arrhythmia, incidental findings, family history), and recommend a systematic, multi - parameter approach for diagnosis and evaluation.

2. **Multidisciplinary Approach**: Suggest the use of multidisciplinary team cooperation to strengthen the close collaboration between expert cardiomyopathy centers and local services.

3. **Diagnostic Process**: Recommend a diagnostic process that combines cardiac and extracardiac features to determine the specific etiological diagnosis, many of which are hereditary, so as to achieve etiologically - based management recommendations.

4. **Phenotype Description**: Phenotype cardiomyopathy subtypes according to key myocardial morphological and functional characteristics, including myocardial scarring seen on cardiac magnetic resonance imaging (MRI). These phenotypic classifications include hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), non - dilated left ventricular cardiomyopathy (NDLVC), arrhythmogenic right ventricular cardiomyopathy, and restrictive cardiomyopathy.

5. **Role of Cardiac MRI**: Emphasize the central role of cardiac MRI in the diagnosis of cardiomyopathy patients and their relatives, and point out its importance in prognosis and treatment decision - making.

6. **Genetic Testing**: Recommend genetic testing in the clinical examination of cardiomyopathy patients and provide genetic counseling. For probands, this helps to confirm the etiological diagnosis and, in some cases, has prognostic significance, guiding treatment and reproductive management. For relatives, cascade genetic testing can exclude individuals who do not carry family variants, relieving them from clinical follow - up.

7. **Cardiac Myosin Inhibitors**: Recommend cardiac myosin inhibitors (such as mavacamten) as second - line treatment drugs for adult symptomatic obstructive HCM.

8. **Sudden Death Risk Stratification**: Recommend the use of validated risk prediction scores/algorithms for individualized sudden death risk assessment as an auxiliary tool for shared decision - making.

9. **Genotype - Based Sudden Death Risk Prediction**: Particularly emphasize that in DCM/NDLVC, identifying high - risk genotypes and accompanying clinical features is of great significance for the implantation decision of implantable cardioverter - defibrillators (ICD).

10. **Personalized Exercise Prescription**: Recommend personalized exercise prescriptions and regular low - to - moderate - intensity exercise for all cardiomyopathy patients, and provide more detailed suggestions for different cardiomyopathy phenotypes (including gene carriers).

Through these key topics, the guideline aims to provide comprehensive and systematic guidance for the diagnosis, evaluation, and management of cardiomyopathies.